Skip to main content

Recurrent Urinary Tract Infection

0
Pipeline Programs
3
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Innovation Pharmaceuticals
1 program
Mineral waterN/A1 trial
Active Trials
NCT02444975Completed140Est. Jul 2016
IBSA Institut Biochimique
IBSA Institut BiochimiqueSwitzerland - Lugano-Pazzallo
1 program
Ialuril 50ml PrefillPHASE_41 trial
Active Trials
NCT05652374Recruiting100Est. Oct 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
IBSA Institut BiochimiqueIaluril 50ml Prefill
Innovation PharmaceuticalsMineral water

Clinical Trials (2)

Total enrollment: 240 patients across 2 trials

Gag Therapy for Recurrent Urinary Tract Infection Assessing Comparability to International Nitrofurantoin Gold Standard Study

Start: Oct 2022Est. completion: Oct 2027100 patients
Phase 4Recruiting

The Effect of Increased Water Intake on the Frequency of the Clinical Recurrent Urinary Tract Infections in Pre-menopausal Women: S-HYDRACYST

Start: Dec 2013Est. completion: Jul 2016140 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 240 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.